Logo image of CRVO

CERVOMED INC (CRVO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CRVO - US15713L1098 - Common Stock

8.76 USD
+0.07 (+0.81%)
Last: 12/8/2025, 11:41:16 AM
Fundamental Rating

3

Taking everything into account, CRVO scores 3 out of 10 in our fundamental rating. CRVO was compared to 531 industry peers in the Biotechnology industry. While CRVO has a great health rating, there are worries on its profitability. CRVO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CRVO had negative earnings in the past year.
CRVO had a negative operating cash flow in the past year.
CRVO had negative earnings in each of the past 5 years.
In the past 5 years CRVO always reported negative operating cash flow.
CRVO Yearly Net Income VS EBIT VS OCF VS FCFCRVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of CRVO (-83.58%) is worse than 70.06% of its industry peers.
CRVO's Return On Equity of -98.36% is in line compared to the rest of the industry. CRVO outperforms 46.52% of its industry peers.
Industry RankSector Rank
ROA -83.58%
ROE -98.36%
ROIC N/A
ROA(3y)-42.82%
ROA(5y)-50.07%
ROE(3y)-49.37%
ROE(5y)-56.44%
ROIC(3y)N/A
ROIC(5y)N/A
CRVO Yearly ROA, ROE, ROICCRVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K 10K 15K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRVO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRVO Yearly Profit, Operating, Gross MarginsCRVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

CRVO has more shares outstanding than it did 1 year ago.
CRVO has more shares outstanding than it did 5 years ago.
CRVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRVO Yearly Shares OutstandingCRVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
CRVO Yearly Total Debt VS Total AssetsCRVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

An Altman-Z score of 4.68 indicates that CRVO is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.68, CRVO is in the better half of the industry, outperforming 72.32% of the companies in the same industry.
CRVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.68
ROIC/WACCN/A
WACCN/A
CRVO Yearly LT Debt VS Equity VS FCFCRVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 6.66 indicates that CRVO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.66, CRVO is in the better half of the industry, outperforming 67.80% of the companies in the same industry.
CRVO has a Quick Ratio of 6.66. This indicates that CRVO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CRVO (6.66) is better than 68.17% of its industry peers.
Industry RankSector Rank
Current Ratio 6.66
Quick Ratio 6.66
CRVO Yearly Current Assets VS Current LiabilitesCRVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for CRVO have decreased strongly by -80.12% in the last year.
The Revenue for CRVO has decreased by -38.81% in the past year. This is quite bad
EPS 1Y (TTM)-80.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.73%
Revenue 1Y (TTM)-38.81%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-83.37%

3.2 Future

The Earnings Per Share is expected to grow by 13.14% on average over the next years. This is quite good.
CRVO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 53.24% yearly.
EPS Next Y-23.71%
EPS Next 2Y0.61%
EPS Next 3Y10.57%
EPS Next 5Y13.15%
Revenue Next Year-45.91%
Revenue Next 2Y-66.34%
Revenue Next 3Y-25.99%
Revenue Next 5Y53.24%

3.3 Evolution

CRVO Yearly Revenue VS EstimatesCRVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
CRVO Yearly EPS VS EstimatesCRVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500 -1K -1.5K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRVO. In the last year negative earnings were reported.
Also next year CRVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRVO Price Earnings VS Forward Price EarningsCRVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRVO Per share dataCRVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.61%
EPS Next 3Y10.57%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRVO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CERVOMED INC

NASDAQ:CRVO (12/8/2025, 11:41:16 AM)

8.76

+0.07 (+0.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2025-11-07/amc
Earnings (Next)03-16 2026-03-16/amc
Inst Owners23.52%
Inst Owner Change-0.21%
Ins Owners24.03%
Ins Owner Change2.01%
Market Cap81.03M
Revenue(TTM)6.16M
Net Income(TTM)-25.58M
Analysts81.54
Price Target22.88 (161.19%)
Short Float %1.76%
Short Ratio1.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.8%
Min EPS beat(2)-8.93%
Max EPS beat(2)-6.67%
EPS beat(4)1
Avg EPS beat(4)-5.85%
Min EPS beat(4)-24.49%
Max EPS beat(4)16.71%
EPS beat(8)2
Avg EPS beat(8)-9.02%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-39.13%
Min Revenue beat(2)-77.68%
Max Revenue beat(2)-0.58%
Revenue beat(4)2
Avg Revenue beat(4)-11.94%
Min Revenue beat(4)-77.68%
Max Revenue beat(4)21.32%
Revenue beat(8)5
Avg Revenue beat(8)6.67%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.77%
PT rev (3m)9.41%
EPS NQ rev (1m)4%
EPS NQ rev (3m)-21.9%
EPS NY rev (1m)-1.95%
EPS NY rev (3m)-10.6%
Revenue NQ rev (1m)-10.78%
Revenue NQ rev (3m)-23.68%
Revenue NY rev (1m)-19.29%
Revenue NY rev (3m)-24.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.15
P/FCF N/A
P/OCF N/A
P/B 3.12
P/tB 3.12
EV/EBITDA N/A
EPS(TTM)-2.9
EYN/A
EPS(NY)-2.01
Fwd EYN/A
FCF(TTM)-2.69
FCFYN/A
OCF(TTM)-2.69
OCFYN/A
SpS0.67
BVpS2.81
TBVpS2.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -83.58%
ROE -98.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.82%
ROA(5y)-50.07%
ROE(3y)-49.37%
ROE(5y)-56.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.66
Quick Ratio 6.66
Altman-Z 4.68
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-80.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.73%
EPS Next Y-23.71%
EPS Next 2Y0.61%
EPS Next 3Y10.57%
EPS Next 5Y13.15%
Revenue 1Y (TTM)-38.81%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-83.37%
Revenue Next Year-45.91%
Revenue Next 2Y-66.34%
Revenue Next 3Y-25.99%
Revenue Next 5Y53.24%
EBIT growth 1Y-114.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-67.9%
EBIT Next 3Y-64.22%
EBIT Next 5Y-24.41%
FCF growth 1Y-197.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-197.44%
OCF growth 3YN/A
OCF growth 5YN/A

CERVOMED INC / CRVO FAQ

What is the fundamental rating for CRVO stock?

ChartMill assigns a fundamental rating of 3 / 10 to CRVO.


What is the valuation status of CERVOMED INC (CRVO) stock?

ChartMill assigns a valuation rating of 0 / 10 to CERVOMED INC (CRVO). This can be considered as Overvalued.


What is the profitability of CRVO stock?

CERVOMED INC (CRVO) has a profitability rating of 0 / 10.


What is the expected EPS growth for CERVOMED INC (CRVO) stock?

The Earnings per Share (EPS) of CERVOMED INC (CRVO) is expected to decline by -23.71% in the next year.